Stefanie Groeneveld-Krentz

Stefanie Groeneveld-Krentz

Auto-generated profile, based on publicly available information

Stefanie Groeneveld-Krentz

Department of Pediatric Oncology Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MSMartin Stanulla
Martin Stanulla
EDElif Dagdan
Elif Dagdan
MZMarketa Zaliova
Marketa Zaliova
AMAnja Möricke
Anja Möricke
CPChiara Palmi
Chiara Palmi
TGthe International BFM Study Group
the International BFM Study Group
Purpose: Somatic deletions that affect the lymphoid transcription factor–coding gene IKZF1 have previously been reported as independently associated with a poor prognosis in pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). We have now refined the prognostic strength of IKZF1 deletions by analyzing the effect of co-occurring deletions.Patients and Methods: The analysis involved 991 patients with BCP ALL treated in the Associazione Italiana Ematologia ed Oncologia Pediatrica–Berlin-Frankfurt-Muenster (AIEOP-BFM) ALL 2000 trial with complete information for copy number alterations of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, Xp22.33/Yp11.31 (PAR1 region; CRLF2, CSF2RA, and IL3RA), and ERG; replication of findings involved 417 patients from the same trial.Results: IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion conferred the worst outcome and, consequently, were grouped as IKZF1plus. The IKZF1plusgroup comprised 6% of patients with BCP ALL, with a 5-year event-free survival of 53 ± 6% compared with 79 ± 5% in patients with IKZF1 deletion who did not fulfill the IKZF1plusdefinition and 87 ± 1% in patients who lacked an IKZF1 deletion ( P ≤ .001). Respective 5-year cumulative relapse incidence rates were 44 ± 6%, 11 ± 4%, and 10 ± 1% ( P ≤ .001). Results were confirmed in the replication cohort, and multivariable analyses demonstrated independence of IKZF1plus. The IKZF1plusprognostic effect differed dramatically in analyses stratified by minimal residual disease (MRD) levels after induction treatment: 5-year event-free survival for MRD standard-risk IKZF1pluspatients was 94 ± 5% versus 40 ± 10% in MRD intermediate- and 30 ± 14% in high-risk IKZF1pluspatients ( P ≤ .001). Corresponding 5-year cumulative incidence of relapse rates were 6 ± 6%, 60 ± 10%, and 60 ± 17% ( P ≤ .001).Conclusion: IKZF1plusdescribes a new MRD-dependent very-poor prognostic profile in BCP ALL. Because current AIEOP-BFM treatment is largely ineffective for MRD-positive IKZF1pluspatients, new experimental treatment approaches will be evaluated in our upcoming trial AIEOP-BFM ALL 2017.

27 November 2014 in Blood
Verified
Journal Article
Open access
PDF file
JIJulie Irving
Julie Irving
EMElizabeth Matheson
Elizabeth Matheson
LMLynne Minto
Lynne Minto
HBHelen Blair
Helen Blair
MCMarian Case
Marian Case
CECornelia Eckert
Cornelia Eckert
Key Points: RAS pathway mutations are prevalent in relapsed childhood ALL, and KRAS mutations are associated with a poorer overall survival. RAS pathway mutations confer sensitivity to mitogen-activated protein kinase kinase inhibitors.

10 August 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JHJana Hof
Jana Hof
SKStefanie Krentz
Stefanie Krentz
CSClaudia van Schewick
Claudia van Schewick
GKGabriele Körner
Gabriele Körner
SSShabnam Shalapour
Shabnam Shalapour
RKRenate Kirschner-Schwabe
Renate Kirschner-Schwabe
Purpose: In the clinical management of children with relapsed acute lymphoblastic leukemia (ALL), treatment resistance remains a major challenge. Alterations of the TP53 gene are frequently associated with resistance to chemotherapy, but their significance in relapsed childhood ALL has remained controversial because of small studies. Patients and Methods: Therefore, we systematically studied 265 first-relapse patients enrolled in the German Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Mü nster 2002 (ALL-REZ BFM 2002) trial for sequence and copy number alterations of the TP53 gene by using direct sequencing and multiplex ligation-dependent probe amplification. Results: We observed copy number and sequence alterations of TP53 in 12.4% (27 of 218) of patients with B-cell precursor ALL and 6.4% (three of 47) of patients with T-cell ALL relapse. Backtracking to initial ALL in 23 matched samples revealed that 54% of all TP53 alterations were gained at relapse. Within B-cell precursor ALL, TP53 alterations were consistently associated with nonresponse to chemotherapy (P < .001) and poor event-free survival (P < .001) and overall survival rates (P = .002). TP53 alterations also had a significant impact on survival within intermediate-risk (S2) and high-risk (S3/S4) relapse patients (P = .007 and P = .019, respectively). This prognostic significance of TP53 alterations was confirmed in multivariate analysis. Besides their clinical impact, TP53 alterations were associated with a higher fraction of leukemic cells in S/G2-M phase of the cell cycle at relapse diagnosis. Conclusion: Alterations of the TP53 gene are of particular importance in the relapse stage of childhood ALL, in which they independently predict high risk of treatment failure in a significant number of patients. Therefore, they will aid in future risk assessment of children with ALL relapse.

15 June 2009 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
ADAntoine Dieudonné-Vatran
Antoine Dieudonné-Vatran
SKStefanie Krentz
Stefanie Krentz
ABAnna M Blom
Anna M Blom
SMSeppo K Meri
Seppo K Meri
BHBirgitta Henriques-Normark
Birgitta Henriques-Normark
BABarbara Albiger
Barbara Albiger
The complement system constitutes an important component of the innate immune system. To colonize their host and/or to cause disease, many pathogens have evolved strategies to avoid complement-mediated bacterial lysis and opsonophagocytosis. In this study, using a collection of 55 clinical isolates of Streptococcus pneumoniae, we demonstrate for the first time that pneumococci bind the complement inhibitor C4b-binding protein (C4BP). C4BP binding seems to be restricted to certain serotypes such as serotype 4, 6B, 7F, and 14, of which the strains of serotype 14 are the strongest binders. We show that bacteria-bound C4BP retains its functional activity and down-regulates the activation of the classical pathway. Thus, this major respiratory pathogen may escape immune recognition and eradication by the complement system. Furthermore, we show that C4BP binding varies between strains but is dependent on the expression of pneumococcal surface protein C, PspC of group 4. The study of the distribution of group 4 pspC locus shows that most of high-binder serotype 14 isolates harbor an allelic variant of group 4 pspC. Using PspC-negative mutant strains, we identified a new allelic variant of PspC (PspC4.4) as a major ligand for C4BP, revealing a new function for this important pneumococcal virulence factor. Thus pneumococci exploit host C4BP for complement evasion in a PspC allele-dependent manner.

7 July 2019 in Cytometry Part A
Verified
Journal Article
Closed access
PDF file
MRMichael Reiter
Michael Reiter
MDMarkus Diem
Markus Diem
ASAngela Schumich
Angela Schumich
MMMargarita Maurer-Granofszky
Margarita Maurer-Granofszky
LKLeonid Karawajew
Leonid Karawajew
FCfor the International Berlin‐Frankfurt‐Münster (iBFM)‐FLOW‐network and the AutoFLOW consortium
for the International Berlin‐Frankfurt‐Münster (iBFM)‐FLOW‐network and the AutoFLOW consortium

1 July 2021 in European Journal of Cancer
Verified
Journal Article
Open access
CECornelia Eckert
Cornelia Eckert
CPCatriona Parker
Catriona Parker
AMAnthony V. Moorman
Anthony V. Moorman
JIJulie Ae. Irving
Julie Ae. Irving
RKRenate Kirschner-Schwabe
Renate Kirschner-Schwabe
VSVaskar Saha
Vaskar Saha
Outcomes of children with high-risk (HR) relapsed acute lymphoblastic leukaemia (ALL) (N = 393), recruited to ALLR3 and ALL-REZ BFM 2002 trials, were analysed. Minimal residual disease (MRD) was assessed after induction and at predetermined time points until haematopoietic stem cell transplantation (SCT). Genetic analyses included karyotype, copy-number alterations and mutation analyses. Ten-year survivals were analysed using Kaplan-Meier and Cox models for multivariable analyses. Outcomes of patients were comparable in ALLR3 and ALL-REZ BFM 2002. The event-free survival of B-cell precursor (BCP) and T-cell ALL (T-ALL) was 22.6% and 26.2% (P = 0.94), respectively, and the overall survival (OS) was 32.6% and 28.2% (P = 0.11), respectively. Induction failures (38%) were associated with deletions of NR3C1 (P = 0.002) and BTG1 (P = 0.03) in BCP-ALL. The disease-free survival (DFS) and OS in patients with good vs poor MRD responses were 57.4% vs 22.6% (P < 0.0001) and 57.8% vs 32.0% (P = 0.0004), respectively. For BCP- and T-ALL, the post-SCT DFS and OS were 42.1% and 56.8% (P = 0.26) and 51.6% and 55.4% (P = 0.67), respectively. The cumulative incidences of post-SCT relapse for BCP- and T-ALL were 36.9% and 17.8% (P = 0.012) and of death were 10.7% and 25.5% (P = 0.013), respectively. Determinants of outcomes after SCT were acute graft versus host disease, pre-SCT MRD (≥10-3), HR cytogenetics and TP53 alterations in BCP-ALL. Improvements in outcomes for HR ALL relapses require novel compounds in induction therapy to improve remission rates and immune targeted therapy after induction to maintain remission after SCT. ALLR3: NCT00967057; ALL REZ-BFM 2002: NCT00114348.